Currently, in addition to the MTOR pathway inhibitor everolimus which is approved for treating breast cancer patients with ER+ disease, additional novel MTOR inhibitors are in early and late-stage clinical trials for the treatment of a wide variety of solid tumors. Here, MTOR is linked to breast carcinoma.